21
September
TCM-Brief-Nonrated-Stellar growth thanks to the low base effect
TCM posted impressive business results in August with revenue of USD19.4mn (+85% yoy) and NPAT of USD1.37mn (versus a loss of USD0.28mn in August 2021). Overall, in 8M22, the company achieved USD127.7mn (+20% yoy) in revenue and USD8.1mn in NPAT (+48% yoy), fulfilling 72% and 75% of its 2022F guidance, respectively.